MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/140/0.1/21.03.25 | Market Closed - Börse Stuttgart 02:23:09 2024-07-03 pm EDT | ||
| 1.52 EUR | -14.61% |
|
| Current month | -4.30% | ||
| 1 month | +33.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 1.52 | -14.61% |
| 24-07-02 | 1.78 | -8.25% |
| 24-07-01 | 1.94 | +4.30% |
| 24-06-28 | 1.86 | -2.11% |
| 24-06-27 | 1.9 | +0.53% |
Delayed Quote Börse Stuttgart
Last update July 03, 2024 at 02:23 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME1GBR |
| ISIN | DE000ME1GBR6 |
| Date issued | 2023-10-03 |
| Strike | 140 $ |
| Maturity | 2025-03-21 (261 Days) |
| Parity | 10 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.04 € |
|---|---|
| Lowest since issue | 0.29 € |
| Spread | 0.07 € |
| Spread % | 4.38% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.59%
- Stock Market
- Warrants
- Warrant
